Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Comparative genomic analysis of tumor tissue and surgical margin distances in esophageal squamous cell carcinoma.

Di Lu, Jianxue Zhai, Zhizhi Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15064

e15064 Background: Surgical resection is crucial for managing esophageal squamous cell carcinoma (ESCC), with emerging evidence indicating that resection...

Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group.

Thomas Jens Ettrich, Waldemar Uhl, Marko Kornmann et al. Jun 01, 2025 pp. 4193-4193 10.1200/jco.2025.43.16_suppl.4193

4193 Background: Perioperative chemotherapy (CTX) in resectable pancreatic ductal adenocarcinoma (rPDAC) is still not considered standard of care and data...

Autologus dendritic cell vaccine in GBM, does geography matter? Retrospective analysis from a single institution in India.

Nitesh Rohatgi, Suman Suryanarayana Karanth, Ankur Bahl et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14023

e14023 Background: Glioblastoma remains a devastating disease, with limited improvements in outcomes despite advancements in surgery and radiotherapy. The...

Real-world outcomes of first-line therapies for unresectable hepatocellular carcinoma in the United States.

Masafumi Ikeda, Sumie Kakehi, Jeremy Snider et al. Jun 01, 2025 pp. 4079-4079 10.1200/jco.2025.43.16_suppl.4079

4079 Background: Unresectable hepatocellular carcinoma (uHCC) remains a significant clinical challenge despite advances in systemic therapies. Real-world...

Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.

Douglas Adkins, Robert I. Haddad, Yungan Tao et al. Jun 01, 2025 pp. 6012-6012 10.1200/jco.2025.43.16_suppl.6012

6012 Background: The addition of immune checkpoint inhibitors to neoadjuvant/adjuvant SOC has led to efficacy benefits across multiple tumor types. The ra...

Exploration of the evolving role of <sup>18</sup> F-FDG PET/CT in evaluating extrahepatic cholangiocarcinoma lymph node metastasis.

Zhihui Gao, Jie Xiao, Tao Suo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16218

e16218 Background: The presence of lymph node metastases at diagnosis is one of the most relevant negative prognostic factors in patients with extrahepati...

Adherence to repeat screening for colorectal cancer using the multi-target stool DNA test: Real-world analysis of patients from federally qualified health centers.

Mallik Greene, Timo Pew, Jorge Zapatier et al. Jun 01, 2025 pp. 3630-3630 10.1200/jco.2025.43.16_suppl.3630

3630 Background: Initial and repeat colorectal cancer (CRC) screening rates are suboptimal and fall short of national goals in adults from historically di...

Stratified analysis of mesothelioma mortality: A 21-year atlas of trends and demographic shifts in the United States.

Fnu Karishma, Shamikha Cheema, Amar Lal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20094

e20094 Background: Mesothelioma is a malignant neoplasm that mostly affects the pleura (85%). With a median survival duration of 12 months, it is classifi...

Comparison of outcomes of minimally invasive surgery and open surgery for rectal cancer.

Vinay C. Bellur, Advaith N. Rao, Ananya Prasad et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15601

e15601 Background: Minimally Invasive Surgery (MIS) is recently gaining traction due to improved intra and peri operative outcomes. In comparison to the c...

A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC).

Bo Wang, Kartik Konduri, Robert M. Jotte et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8126

TPS8126 Background: The addition of atezolizumab (atezo) to both induction therapy and maintenance therapy for patients with ES-SCLC has improved median p...

Prevalence of the HPV, EBV, and TTV viral RNA in the plasma of patients with solid and hematologic neoplasms and the detection of a specific immune signature.

Gustavo Rivero, Ching-Wen Chang, Hong Zhang et al. Jun 01, 2025 pp. 2583-2583 10.1200/jco.2025.43.16_suppl.2583

2583 Background: Epstein−Barr virus (EBV) and human papillomavirus (HPV) are considered human oncoviruses. In contrast, the torque teno virus (TTV) is not...

Clinical outcomes and safety profile of adagrasib in KRAS G12C-mutated solid tumors: A single-arm meta-analysis.

Osama Ahmad, Shree Rath, M Rafiqul Islam et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20648

e20648 Background: KRAS G12C mutations are key oncogenic drivers in multiple solid tumors, including non-small cell lung cancer (NSCLC) and colorectal can...

Role of pirfenidone in the primary prophylaxis of lung cancer in idiopathic pulmonary fibrosis patients: A systematic review and meta-analysis.

Salman J. Khan, Syed Muhammad Ibne Ali Jaffari, Ahmad Basharat et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22514

e22514 Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease associated with a significantly increased risk of developing lung can...

Ex vivo liver resection and auto-transplantation for cholangiocarcinoma.

Yuan Ding, Xin Han, Zhongquan Sun Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16194

e16194 Background: Cholangiocarcinoma (CCA) is an epithelial malignancy with a dismal prognosis. Here, we presented our single-center experience in treati...

Effect of a single home visit on distress in cancer patients undergoing chemotherapy: A comparative study.

Mila Petrova, Sonya Kircheva Draganova, Rosalina Pechlivanova et al. Jun 01, 2025 pp. 12107-12107 10.1200/jco.2025.43.16_suppl.12107

12107 Background: This study aimed to investigate whether a home visit after the first chemotherapy can significantly reduce cancer patients’ psychologica...

Influence of HIV on outcomes in patients with diffuse large B cell lymphoma treated with CD19 targeting CAR-T cell therapy.

Shanawar Ali Waris, Nanda Siva, Nolan Holley et al. Jun 01, 2025 pp. 7076-7076 10.1200/jco.2025.43.16_suppl.7076

7076 Background: HIV+ patients have an 18-fold increased risk of developing diffuse large B Cell Lymphoma (DLBCL). There is uncertainty in the literature...

The use of peripheral intravenous catheters (PIV) for lymphoma patients receiving anthracycline-based chemotherapy: A multicenter real-world analysis (RWA).

Yun Kyoung Ryu Tiger, Joe D. Lukowski, Abdus-Samad Minhaj et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13567

e13567 Background: Given a potential risk of extravasation with vesicants and irritants, central venous catheters (CVCs), such as port-a-cath or periphera...

Prognostic significance of neutrophil-to-lymphocyte ratio in small cell lung cancer in the era of immunotherapy.

Bhavesh Mohan Lal, Nikhila Sampath Kumar, Jackson Hoesley et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20129

e20129 Background: Cancer-related inflammation is evident in the peripheral blood as neutrophilia and/or lymphopenia. Previous studies have demonstrated i...

Chylopericardium and chylous effusions during treatment with selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC).

Alvaro Guimaraes Paula, Ximeng Liu, Simon Heeke et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20694

e20694 Background: Selective RET tyrosine kinase inhibitors (RETi) revolutionized the treatment of patients (pts) with advanced NSCLC harboring RET fusion...

Evaluating inflammatory biomarkers as predictors of outcomes and immune-related adverse events (irAE) in the Big Ten Cancer Research Consortium (BTCRC) LUN16-081 phase II clinical trial.

Greg Andrew Durm, Sandra K. Althouse, Hirva Mamdani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20087

e20087 Background: Immune checkpoint inhibition has improved patient outcomes across nearly every stage of NSCLC, and consolidation immunotherapy has beco...

A novel prognostic model to optimize the timing of docetaxel (Doc) following an androgen receptor pathway inhibitor (ARPi) in metastasic castration-resistant prostate cancer (mCRPC).

Lola Rodríguez Nogueira, Rodrigo España, María Ruiz Vico et al. Jun 01, 2025 pp. 5063-5063 10.1200/jco.2025.43.16_suppl.5063

5063 Background: ARPi has become a standard of care for advanced prostate cancer due to its activity and safety profile. DoC is a therapeutic alternative...

An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19).

Yu Sunakawa, Chiaki Inagaki, Satoshi Yuki et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3637

TPS3637 Background: The FRESCO-1/2 trials demonstrated a survival benefit of fruquintinib (FRU) in mCRC after 3rd-line therapy. FRU can be considered as o...

Differential patterns of cell surface marker expression in clinically relevant subgroups of non-small cell lung cancer.

John Smestad, Muhammad Furqan, Aliasger K. Salem Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20553

e20553 Background: Antibody-drug conjugates (ADC) and bispecific antibodies have an increasing role in solid tumors including thoracic malignancies. In th...

Sex-based differences in outcomes following minimally invasive gastrectomy for gastric cancer: A nationwide study.

Dhaval Patel, Aneri Sanepara, Naineel Vishnubhai Patel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16058

e16058 Background: Gastric cancer is projected to affect 17,720 men and 12,580 women in 2025, according to the American Cancer Society. Minimally invasive...

Impact of alcohol use disorder on outcomes in gastrointestinal cancer patients: A National Inpatient Sample analysis.

Yashwitha Sai Pulakurthi, Praneeth Reddy Keesari, Sreeram Pannala et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16485

e16485 Background: Alcohol is not only known to be a risk factor for many gastrointestinal malignancies but also affects its management and outcomes. The...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page